| Literature DB >> 33385160 |
Stephan Sacher1, Anna Peter1, Johannes G Khinast1,2.
Abstract
The feasibility of Optical Coherence Tomography (OCT) for in-line monitoring of pharmaceutical film coating processes has recently been demonstrated. OCT enables real-time acquisition of high-resolution cross-sectional images of coating layers and computation of coating thickness. In addition, coating quality attributes can be computed based on in-line data. This study assesses the in-line applicability of OCT to various coating functionalities and formulations. Several types of commercial film-coated tablets containing the most common ingredients were investigated. To that end, the tablets were placed into a miniaturized perforated drum. An in-line OCT system was used to monitor the tablet bed. This set-up resembles the final stage of an industrial pan coating process. All investigated coatings were measured, and the coating thickness, homogeneity and roughness were computed. The rotation rate was varied in a range comparable to large-scale coating operations, and no influence on the outcome was observed. The results indicate that OCT can be used to determine end-point and establish in-process control for a wide range of coating formulations. The real-time computation of coating homogeneity and roughness can support process optimization and formulation development.Entities:
Keywords: Coating homogeneity; Coating roughness; In-line monitoring,tablet coating; Optical coherence tomography
Year: 2020 PMID: 33385160 PMCID: PMC7772539 DOI: 10.1016/j.ijpx.2020.100067
Source DB: PubMed Journal: Int J Pharm X ISSN: 2590-1567
Tablets, coating ingredients and coating functionality.
| Brand name | Film-forming polymer | Plasticiser | Other ingredients | Coating functionality | Tablet shape | Tablet size | Tablet photo |
|---|---|---|---|---|---|---|---|
| RatioDolor | HPMC | PEG, Glycerol | Cosmetic | Oval | 19.3 × 8.3 × 5.3 | ||
| Glucophage | HPMC | Cosmetic | Round, biconvex | 13.6 × 6.6 | |||
| Zinkorotat POS | Eudragit L | Triethyl citrate | Talcum | Delayed release | Round, biconvex | 9.3 × 4.9 | |
| Thrombo ASS | Eudragit L | Triacetin | Talcum | Delayed release | Round, biconvex with small bevel edge | 7.3 × 4 | |
| Pantoloc | HPMC, PVP | Propylene glycol | Titanium dioxide, yellow iron oxide | Inner layer, isolation | Oval, biconvex | 11.7 × 6 × 4 | |
| Eudragit L30D | Triethyl citrate | Yellow, red and black iron oxide | Top layer delayed release | ||||
| Pantoprazol | HPMC | Triethyl citrate | SCMS | Inner layer, isolation | Oval, biconvex | 9.3 × 4.9 | |
| Eudragit L30D | Triethyl citrate | Yellow iron oxide | Top layer delayed release | ||||
| Pharm 1 | HPMC, CA | PEG | Opadry, Opacode black ink | Osmotic release (controlled release) | Round, biconvex | 8 × 4 | |
| Pharm 2 | HPMC, CA | PEG | Osmotic release (controlled release) | Round, biconvex | 11.3 × 6 | ||
| Pharm 3 | HPMC, CA, hydroxypropyl cellulose | PEG, Triacetin | Extended release | Oval, biconvex | 10.8 × 5.5 × 4.4 |
HPMC = hydroxypropyl methylcellulose, CA = cellulose acetate, PEG = polyethylene glycol, PVP = polyvinylpyrrolidon, SCMS = sodium carboxymethyl starch, d = tablet diameter, h = tablet height, l = tablet length, w = tablet width.
Fig. 1At-line sampling device with a rotating drum and an in-line OCT sensor. The insert shows the moving tablet bed in the drum.
Fig. 2Definition of coating thickness, homogeneity and roughness.
Fig. 3Images of commercial tablet coatings acquired using the OCT in-line sensor. The scale bar represents the coating layer dimension.
Fig. 4Images of commercial tablet coatings acquired using the light microscope in the reflectance mode with 200 fold magnification.
Tablet coating attributes computed using the OCT data and coating thickness obtained via light microscopic (LM) imaging.
| Tablet | at 20 rpm | at 30 rpm | at 40 rpm | LM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean Coating Thickness [μm] and RSD | Mean Coating Homogeneity [%] and RSD | Mean Coating Roughness [μm] and RSD | Mean Coating Thickness [μm] and RSD | Mean Coating Homogeneity [%] and RSD | Mean Coating Roughness [μm] and RSD | Mean Coating Thickness [μm] and RSD | Mean Coating Homogeneity [%] and RSD | Mean Coating Roughness [μm] and RSD | Mean Coating Thickness [μm] and RSD | |
| RatioDolor | 15.5 ± 14.7 | 41.9 ± 50.6 | 1.9 ± 24.5 | 15.5 ± 13.6 | 34.6 ± 53.5 | 1.9 ± 20.1 | 15.7 ± 13.3 | 42.6 ± 44.9 | 1.9 ± 50.4 | – |
| Glucophage | 21.5 ± 24.7 | 41.9 ± 39.4 | 1.4 ± 15.0 | 20.7 ± 21.3 | 55.9 ± 29.0 | 1.4 ± 11.3 | 19.9 ± 20.1 | 50.0 ± 32.4 | 1.4 ± 11.1 | – |
| Zinkorotat POS | 63.9 ± 13.5 | 57.2 ± 37.2 | 3.3 ± 52.5 | 64.2 ± 12.8 | 55.8 ± 33.4 | 3.4 ± 50.7 | 63.5 ± 12.4 | 62.9 ± 27.6 | 3.3 ± 46.5 | 67.2 ± 6.8 |
| Thrombo ASS | 52.2 ± 19.7 | 51.9 ± 47.6 | 3.7 ± 43.1 | 50.5 ± 15.2 | 49.3 ± 47.6 | 3.6 ± 38.1 | 51.2 ± 15.0 | 49.7 ± 44.7 | 3.7 ± 36.4 | 50.1 ± 15.5 |
| Pantoloc | 77.5 ± 12.3 | 98.2 ± 1.5 | 2.9 ± 57.1 | 76.2 ± 11.9 | 97.9 ± 1.8 | 3.4 ± 47.6 | 76.0 ± 12.6 | 97.9 ± 1.9 | 3.8 ± 49.8 | 73.7 ± 14.9 |
| Pantoprazol | 156.2 ± 11.3 | 86.5 ± 7.3 | 5.3 ± 60.7 | 157.8 ± 11.1 | 86.4 ± 5.8 | 4.1 ± 62.1 | 157.1 ± 11.6 | 89.2 ± 6.3 | 5.4 ± 63.8 | 162.4 ± 7.8 |
| Pharm1 | 79.3 ± 11.6 | 96.0 ± 3.7 | 4.0 ± 57.0 | 78.5 ± 11.0 | 95.9 ± 2.6 | 3.4 ± 55.0 | 77.9 ± 11.0 | 96.5 ± 2.9 | 3.7 ± 56.4 | 81.6 ± 8.1 |
| Pharm2 | 58.7 ± 13.2 | 81.1 ± 6.8 | 4.6 ± 28.1 | 58.6 ± 11.9 | 82.2 ± 5.8 | 4.3 ± 28.1 | 59.9 ± 12.2 | 84.6 ± 4.9 | 4.2 ± 28.9 | 63.8 ± 8.2 |
| Pharm3 | 75.3 ± 11.4 | 92.9 ± 6.7 | 3.2 ± 52.9 | 74.3 ± 10.5 | 94.1 ± 5.1 | 3.2 ± 47.2 | 74.4 ± 10.8 | 94.1 ± 4.6 | 3.6 ± 47.5 | 82.6 ± 7.7 |
Fig. 5Coating thickness measurement in the LM image.